SOUTH SAN FRANCISCO, Calif., March 24 /PRNewswire-FirstCall/ -- Renovis, Inc. announced today that Chief Financial Officer John C. Doyle will be presenting at the Smith Barney Citigroup 2005 Healthcare Conference in Washington, DC. The presentation will be webcast live via the internet, on March 29, 2005 at 9:25 am EST. To access the live webcast, please visit Renovis’ homepage, http://www.renovis.com/. An archived version of the webcast will be available in the same location for 7 days following the presentation.
About Renovis
Renovis is a biopharmaceutical company developing drugs to treat neurological diseases and disorders. Our most advanced product candidate, CEROVIVE(R) (NXY-059), is in Phase III clinical trials for acute ischemic stroke with our exclusive licensee, AstraZeneca AB. CEROVIVE(R) (NXY-059) is a novel free radical trapping neuroprotectant which reduces infarct size and preserves brain function in experimental models of acute ischemic stroke. We are independently developing REN-1654, an oral drug candidate for neuropathic pain in a Phase II clinical trial for sciatica and REN-850, an oral drug candidate for multiple sclerosis in a Phase I clinical trial. Our research and development programs focus on major medical needs in the areas of neuroprotection, pain and neuroinflammatory diseases.
For additional information about the company, please visit http://www.renovis.com/.
CEROVIVE (NXY-059) is a registered trademark of the AstraZeneca group of companies. All other product names and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Renovis cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make, including risks related to: our heavy dependence on the success of Cerovive(R) (NXY-059), which is still under development; our dependence on our strategic collaboration with AstraZeneca; AstraZeneca’s success in obtaining regulatory approval to market Cerovive(R) (NXY-059); our ability to successfully develop other product candidates; obtaining, maintaining and protecting the intellectual property incorporated into our product candidates; and our ability to obtain additional funding to support our business activities. These and other risks are described in greater detail in the “Risk Factors” section of our Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission on November 15, 2004. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make. We do not assume any obligation to update any forward-looking statements.
Contacts: INVESTORS: MEDIA: Renovis, Inc. Noonan/Russo John C. Doyle Emily Poe (650) 266-1407 212-845-4266 doyle@renovis.comemily.poe@eurorscg.com
Renovis, Inc.
CONTACT: Investors, John C. Doyle of Renovis, +1-650-266-1407,doyle@renovis.com; or Media, Emily Poe of Noonan/Russo, +1-212-845-4266,emily.poe@eurorscg.com for Renovis
